2006
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Abstract: Aptamers are oligonucleotide ligands that are selected for high-affinity binding to molecular targets. Pegaptanib sodium (Macugen; Eyetech Pharmaceuticals/Pfizer) is an RNA aptamer directed against vascular endothelial growth factor (VEGF)-165, the VEGF isoform primarily responsible for pathological ocular neovascularization and vascular permeability. After nearly a decade of preclinical development to optimize and characterize its biological effects, pegaptanib was shown in clinical trials to be effective in …
Search citation statements
Paper Sections
Select...
1,201
347
106
34
Citation Types
4
1,117
0
22
Year Published
Range
2005
2027
Publication Types
Select...
1,286
166
99
58
Relationship
1
1,608
Authors
Journals
Cited by 1,606 publications
(1,143 citation statements)
References 88 publications
4
1,117
0
22
Smart CitationsHow the paper below cites the one you are viewing
“…Transparency measurements give insight into the homogeneity of the gels, allowing us to correlate, at least in part, the nonlinear changes in swelling, mechanics, and degradation noted in the previous sections to potential phase separation within these materials. Optical transparency is also an important parameter in some applications of injectable hydrogels (e.g., ophthalmic delivery) that are particular targets for protein-based therapies . Transmittance as a function of temperature was measured by ramping the temperature of a microplate reader from 25 to 40 °C and tracking the resulting transmittance at 595 nm, far outside the window in which any of the components of any of the combinatorial hydrogels would absorb due to chemical bonding; as such, the transmittance measurement corresponds to the light scattered by each hydrogel and, by extension, the number and size of phase-separated domains present in each hydrogel sample.…”
Section: Results
supporting
confidence: 87%
Abstract